Log In
Print
BCIQ
Print
Print this Print this
 

serlopitant (VPD-737) (formerly MK-0594)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionNeurokinin-1 (NK-1; Substance P) receptor antagonist
Molecular Target Neurokinin 1 (NK1) Substance P receptor (TACR1)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationItch
Indication DetailsTreat chronic pruritus
Regulatory Designation

Partner

Tigercat Pharma Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today